These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38855103)

  • 1. Pan-cancer analysis predict that FAT1 is a therapeutic target and immunotherapy biomarker for multiple cancer types including non-small cell lung cancer.
    Ding C; Huang H; Wu D; Chen C; Hua Y; Liu J; Li Y; Liu H; Chen J
    Front Immunol; 2024; 15():1369073. PubMed ID: 38855103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of FAT1 in Lung Adenocarcinoma and Its Relationship 
with Immune Cell Infiltration].
    Ding C; Zhao W; Huang H; Li Y; Zhang Z; Zhang R; Wang Y; Wu D; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):109-117. PubMed ID: 38453442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fat1 suppresses the tumor-initiating ability of nonsmall cell lung cancer cells by promoting Yes-associated protein 1 nuclear-cytoplasmic translocation.
    Li M; Zhong Y; Wang M
    Environ Toxicol; 2021 Nov; 36(11):2333-2341. PubMed ID: 34390292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-183-5p overexpression orchestrates collective invasion in salivary adenoid cystic carcinoma through the FAT1/YAP1 signaling pathway.
    Chen BJ; Jiang J; Li T; Jiang HJ; Liang XH; Tang YL
    Biochem Biophys Res Commun; 2023 May; 655():127-137. PubMed ID: 36934588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer.
    Hu X; Zhai Y; Kong P; Cui H; Yan T; Yang J; Qian Y; Ma Y; Wang F; Li H; Cheng C; Zhang L; Jia Z; Li Y; Yang B; Xu E; Wang J; Yang J; Bi Y; Chang L; Wang Y; Zhang Y; Song B; Li G; Shi R; Liu J; Zhang M; Cheng X; Cui Y
    Cancer Lett; 2017 Jul; 397():83-93. PubMed ID: 28366557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human FAT1 cadherin controls cell migration and invasion of oral squamous cell carcinoma through the localization of β-catenin.
    Nishikawa Y; Miyazaki T; Nakashiro K; Yamagata H; Isokane M; Goda H; Tanaka H; Oka R; Hamakawa H
    Oncol Rep; 2011 Sep; 26(3):587-92. PubMed ID: 21617878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer.
    Zhang W; Ji K; Min C; Zhang C; Yang L; Zhang Q; Tian Z; Zhang M; Wang X; Li X
    Cancer Sci; 2023 Jan; 114(1):63-74. PubMed ID: 35524544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAT1 inhibits cell migration and invasion by affecting cellular mechanical properties in esophageal squamous cell carcinoma.
    Hu X; Zhai Y; Shi R; Qian Y; Cui H; Yang J; Bi Y; Yan T; Yang J; Ma Y; Zhang L; Liu Y; Li G; Zhang M; Cui Y; Kong P; Cheng X
    Oncol Rep; 2018 May; 39(5):2136-2146. PubMed ID: 29565465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protumorigenic role of the atypical cadherin FAT1 by the suppression of PDCD10 via RelA/miR221-3p/222-3p axis in glioblastoma.
    Malik N; Kundu A; Gupta Y; Irshad K; Arora M; Goswami S; Mahajan S; Sarkar C; Suri V; Suri A; Chattopadhyay P; Sinha S; Chosdol K
    Mol Carcinog; 2023 Dec; 62(12):1817-1831. PubMed ID: 37606187
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Chen C; Li Y; Liu H; Liao M; Yang J; Liu J
    Heliyon; 2024 Apr; 10(7):e28356. PubMed ID: 38560204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NFкB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma.
    Srivastava C; Irshad K; Gupta Y; Sarkar C; Suri A; Chattopadhyay P; Sinha S; Chosdol K
    BMC Cancer; 2020 Jan; 20(1):62. PubMed ID: 31992226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells.
    Dikshit B; Irshad K; Madan E; Aggarwal N; Sarkar C; Chandra PS; Gupta DK; Chattopadhyay P; Sinha S; Chosdol K
    Oncogene; 2013 Aug; 32(33):3798-808. PubMed ID: 22986533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function and cancer genomics of FAT family genes (review).
    Katoh M
    Int J Oncol; 2012 Dec; 41(6):1913-8. PubMed ID: 23076869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pan-cancer analysis of the FAT1 in human tumors.
    Wang Z; Lin K; Xiao H
    Sci Rep; 2022 Dec; 12(1):21598. PubMed ID: 36517565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene.
    Xu J; Wang B; Liu ZT; Lai MC; Zhang ML; Zheng SS
    Math Biosci Eng; 2019 Dec; 17(2):1534-1547. PubMed ID: 32233593
    [No Abstract]   [Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding.
    Wojtalewicz N; Sadeqzadeh E; Weiß JV; Tehrani MM; Klein-Scory S; Hahn S; Schmiegel W; Warnken U; Schnölzer M; de Bock CE; Thorne RF; Schwarte-Waldhoff I
    PLoS One; 2014; 9(3):e90461. PubMed ID: 24625754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
    Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.